Beam Therapeutics (BEAM) Non-Current Deffered Revenue (2020 - 2025)

Beam Therapeutics (BEAM) has 6 years of Non-Current Deffered Revenue data on file, last reported at $10.2 million in Q3 2025.

• Non-Current Deffered Revenue for Q3 2025 came in at $10.2 million, down 82.43% year-over-year; the trailing twelve-month figure through Sep 2025 was $10.2 million (down 82.43% YoY), and the FY2024 annual result was $33.2 million, down 69.77% from the prior year.
• Non-Current Deffered Revenue eased to $10.2 million in Q3 2025 per BEAM's latest filing, from $20.3 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $262.3 million in Q4 2021 and troughed at $10.2 million in Q3 2025.
• A 5-year average of $115.7 million and a median of $104.7 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2025: Non-Current Deffered Revenue soared 66474.37% in 2021, then plunged 82.43% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $262.3 million in 2021, then fell by 22.92% to $202.2 million in 2022, then tumbled by 45.65% to $109.9 million in 2023, then plunged by 69.77% to $33.2 million in 2024, then sank by 69.41% to $10.2 million in 2025.
• Business Quant data shows BEAM's Non-Current Deffered Revenue at $10.2 million in Q3 2025, $20.3 million in Q2 2025, and $49.4 million in Q1 2025.